Structure of Vigabatrin
CAS No.: 68506-86-5
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Vigabatrin is a structural analog of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) that irreversibly inhibits the catabolism of GABA by GABA transaminase.
Synonyms: γ-Vinyl-GABA
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
| CAS No. : | 68506-86-5 |
| Formula : | C6H11NO2 |
| M.W : | 129.16 |
| SMILES Code : | C=CC(N)CCC(O)=O |
| Synonyms : |
γ-Vinyl-GABA
|
| MDL No. : | MFCD00274577 |
| InChI Key : | PJDFLNIOAUIZSL-UHFFFAOYSA-N |
| Pubchem ID : | 5665 |
| GHS Pictogram: |
|
| Signal Word: | Warning |
| Hazard Statements: | H315-H319-H335 |
| Precautionary Statements: | P261-P305+P351+P338 |
Clinical Trial:
| NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
| NCT02205931 | Epilepsy | Phase 4 | Recruiting | June 2019 | United Kingdom ... More >> Birmingham Children's Hospital Recruiting Birmingham, United Kingdom, B4 6NH Contact: Shakti Agrawal, MBBS 0044 1213338149 shakti.agrawal@bch.nhs.uk Principal Investigator: Shakti Agrawal, MBBS Bristol Royal Hospital for Children Recruiting Bristol, United Kingdom, BS2 8AE Contact: Andrew Mallick, FRCPCH Principal Investigator: Andrew Mallick Addenbrooke's Hospital Recruiting Cambridge, United Kingdom, CB2 0QQ Contact: Alasdair Parker, MA 0044 1223 245151 alasdair.parker@addenbrookes.nhs.uk Principal Investigator: Alasdair Parker, MA Lancashire Teaching Hospitals NHS Foundation Trust Recruiting Lancashire, United Kingdom Contact: Helen Basu Helen.Basu@lthtr.nhs.uk Principal Investigator: Helen Basu Leeds Teaching Hospital Recruiting Leeds, United Kingdom, LS1 3EX Contact: Helen McCullagh, RCPCH 0044 113 243 2799 h.mccullagh@nhs.net Principal Investigator: Helen McCullagh, RCPCH Alder Hey Children's Hospital Recruiting Liverpool, United Kingdom, L12 2AP Contact: Rachel Kneen, BMBS 0044 151 2525163 rachel.kneen@liverpool.ac.uk Principal Investigator: Rachel Kneen, BMBS Great Ormond Street Hospital Recruiting London, United Kingdom, WC1N 3JH Contact: Christin Eltze, MD Res 0044 207 405 9200 ext 5438 christin.eltze@gosh.nhs.uk Principal Investigator: Christin Eltze, MD Res St George's University Hospitals NHS Foundation Trust Recruiting London, United Kingdom Contact: Penny Fallon Penny.Fallon@stgeorges.nhs.uk Principal Investigator: Penny Fallon Royal Manchester Children's Hospital Recruiting Manchester, United Kingdom, M13 0JE Contact: Tim Martland, RCPCH 0044 161 276 1234 timothy.martland@cmft.nhs.uk Principal Investigator: Tim Martland, RCPCH The Newcastle Upon Tyne Hospitals NHS Foundation Trust Recruiting Newcastle upon Tyne, United Kingdom Contact: Anita Devlin Anita.Devlin@nuth.nhs.uk Principal Investigator: Anita Devlin Sheffield Children's NHS Foundation Trust Recruiting Sheffield, United Kingdom Contact: Archana Desurkar Archana.Desurkar@sch.nhs.uk Principal Investigator: Archana Desurkar Less << |
| NCT00552526 | Epilepsy Ment... More >>al Retardation Less << | Phase 4 | Unknown | December 2013 | Norway ... More >> SSE, Nevrological dep. , Rikshospitalet University hospital Oslo, Norway Less << |
| NCT03636958 | Refractory Epilepsy | Not Applicable | Not yet recruiting | December 2022 | France ... More >> Assistance Publique Des Hopitaux de Marseille Not yet recruiting Marseille, Paca, France, 13354 Contact: STANISLAS LAGARDE, MD +33 491385554 Stanislas.LAGARDE@ap-hm.fr Less << |
| NCT01006811 | Infantile Spasms | Phase 2 Phase 3 | Completed | - | India ... More >> All India Institute of Medical Sciences New Delhi, Delhi, India, 110049 Less << |
| NCT01767779 | - | Active, not recruiting | December 2018 | United States, Alabama ... More >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, California UCLA Los Angeles, California, United States, 90095 United States, Massachusetts Boston Children's Hospital Boston, Massachusetts, United States, 02115 United States, Ohio Cincinnati Children's Hospital Cincinnati, Ohio, United States, 45229 United States, Texas University of Texas in Houston Houston, Texas, United States, 77030 Less << | |
| NCT01390909 | - | Completed | - | - | |
| NCT01723787 | - | Active, not recruiting | October 2018 | United States, Colorado ... More >> Children's Hospital Colorado Aurora, Colorado, United States, 80045 Less << | |
| NCT01390909 | - | Completed | - | - | |
| NCT01549288 | Infantile Spasms | Phase 2 Phase 3 | Withdrawn | December 2013 | India ... More >> Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital New Delhi, Delhi, India, 110001 Less << |
| NCT00001489 | - | Completed | - | United States, Maryland ... More >> National Institute of Neurological Disorders and Stroke (NINDS) Bethesda, Maryland, United States, 20892 Less << | |
| NCT00626834 | Cocaine Addiction | Phase 1 | Completed | - | United States, Texas ... More >> University of Texas Health Science Center San Antonio, Texas, United States, 78229 Less << |
| NCT00527683 | Cocaine Dependence | Phase 2 | Completed | - | Mexico ... More >> Clinica Integral de Tratamiento Contra las Adicciones SA de CV Mexico City, Mexico, D.F., Mexico, 11560 Less << |
| NCT00506935 | Methamphetamine Addiction | Phase 1 | Completed | - | United States, California ... More >> UCLA Los Angeles, California, United States, 90024 Less << |
| NCT00611130 | Cocaine Dependence | Phase 2 | Completed | - | United States, Arkansas ... More >> Addiction Treatment Clinic Little Rock, Arkansas, United States United States, California St. Luke's Hospital Addiction Pharmacology Research Laboratory San Francisco, California, United States, 94110 Friends Research Institute Torrance, California, United States United States, Florida Operation PAR Largo, Florida, United States Segal Institute for Clinical Research North Miami, Florida, United States, 33161 United States, Maryland Johns Hopkins Bayview Medical Center Center for Chemical Dependence Baltimore, Maryland, United States United States, Massachusetts Boston University School of Medicine Boston, Massachusetts, United States United States, New York New York University Mental Health and Addictive Disorders Research Program New York, New York, United States United States, Ohio Cincinnati Addiction Research Center (CinARC) Cincinnati, Ohio, United States Dayton Veterans Affairs Medical Center Dayton, Ohio, United States United States, Texas University of Texas Health Science Center at San Antonio San Antonio, Texas, United States Less << |
| NCT00730522 | Methamphetamine Dependence | Phase 2 | Terminated(To conserve remaini... More >>ng capital, Sponsor decided to terminate the study early.) Less << | - | United States, California ... More >> North County Clinical Research (NCCR) Oceanside, California, United States South Bay Treatment Center San Diego, California, United States Addiction Pharmacology Research Laboratory, St. Luke's Hospital San Francisco, California, United States United States, Missouri START Research and Treatment Kansas City, Missouri, United States United States, Nebraska Creighton University Medical Center Omaha, Nebraska, United States United States, New Mexico Behavioral Health Research Center of the Southwest Albuquerque, New Mexico, United States United States, Oklahoma Pahl Pharmaceutical Research Oklahoma City, Oklahoma, United States United States, Texas Pillar Research Dallas, Texas, United States Less << |
| NCT00373581 | Cocaine Dependence | Phase 2 | Terminated(Funding ran out) | - | United States, New York ... More >> Irving Center for Clinical Research New York, New York, United States, 10032 Less << |
| NCT03421496 | Infantile Spasm | Phase 3 | Recruiting | December 2019 | United States, Florida ... More >> Nicklaus Children's Hospital Recruiting Miami, Florida, United States, 33155 Contact: Research Coordinator 786-624-3611 Abel.Ortega@Nicklaushealth.org United States, Michigan Beaumont Children's Hospital Recruiting Royal Oak, Michigan, United States, 48073 Contact: Research Coordinator 248-551-3302 Elizabeth.Kring@beaumont.org United States, Ohio Akron Children's Hospital Recruiting Akron, Ohio, United States, 44308 Contact: Research Coordinator 330-543-0690 jkatz@akronchildrens.org United States, Oregon Oregon Health & Science University Recruiting Portland, Oregon, United States, 97239 Contact: Research Coordinator 503-418-8297 mccarbry@ohsu.edu United States, Washington Institute for Research and Innovation | MultiCare Health System Recruiting Tacoma, Washington, United States, 98405 Contact: Research Coordinator 253-403-9348 ccanorro@multicare.org Less << |
| NCT03003143 | Autoimmune Encephalopathy | Not Applicable | Recruiting | August 2018 | Korea, Republic of ... More >> Seoul National University Hospital Recruiting Seoul, Korea, Republic of Contact: Kon Chu, Professor stemcell.snu@gmail.com Contact: JIN-SUN JUN, Fellow junjinsun0401@gmail.com Principal Investigator: Kon Chu, MD, PhD. Less << |
| NCT00611130 | - | Completed | - | - | |
| NCT01281202 | Cocaine Addiction ... More >> Cocaine Dependence Less << | Phase 2 Phase 3 | Completed | - | United States, California ... More >> Matrix Institute on Addictions Los Angeles, California, United States, 90016 Friends Research Institute Torrance, California, United States, 90502 United States, Colorado VA Medical Center Denver, Colorado, United States, 80220 United States, Florida University of Miami School of Medicine Miami, Florida, United States, 33136 United States, Illinois NeuroPsychiatric Research & Practice Assoc., Ltd. Oak Brook, Illinois, United States, 60523 United States, Maryland Mountain Manor Treatment Center @ Baltimore Baltimore, Maryland, United States, 21229 United States, Massachusetts Boston University School of Medicine Boston, Massachusetts, United States, 02118 United States, New Mexico Pacific Institute for Research and Evaluation Albuquerque, New Mexico, United States, 87102 United States, Pennsylvania Western Psychiatric Inst. and Clinic Pittsburgh, Pennsylvania, United States, 15213 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29403 United States, Texas Pillar Clinical Research, LLC Dallas, Texas, United States, 75243 University of Texas Health Science Center at Houston Houston, Texas, United States, 77054 United States, Utah George E Wahlen VA Medical Center Salt Lake City, Utah, United States, 84148 Less << |
| NCT01281202 | - | Completed | - | - | |
| NCT01335867 | Alcoholism Co... More >>caine Dependence Less << | Phase 2 | Terminated | - | United States, Pennsylvania ... More >> University of Pennsylvania, Treatment Research Center Philadelphia, Pennsylvania, United States, 19104 Less << |
| NCT01278173 | Adult Refractory Complex Parti... More >>al Seizures Less << | Phase 4 | Completed | - | - |
| NCT01335867 | - | Terminated | - | - | |
| NCT01278173 | - | Completed | - | - | |
| NCT01073579 | - | Completed | - | - | |
| NCT02299115 | Infantile Spasms | Phase 3 | Recruiting | March 2021 | Canada, Ontario ... More >> Hospital for Sick Children Recruiting Toronto, Ontario, Canada, M5G1X8 Contact: Cristina Go, MD 416-813-7353 cristina.go@sickkids.ca Principal Investigator: Carter Snead, MD Sub-Investigator: Kevin C Jones, MD Sub-Investigator: Blathnaid McCoy, MD Sub-Investigator: Ayako Ochi, MD Sub-Investigator: Jennifer Boyd, RN,MSCN Less << |
| NCT03347526 | Infantile Spasm | Phase 3 | Enrolling by invitation | August 2021 | United States, Colorado ... More >> University of Colorado Anschutz Medical Campus Aurora, Colorado, United States, 80045 Less << |
| NCT01266291 | - | Terminated(Was not possible to... More >> enroll sufficient number of subjects to draw any worthwhile conclusions from the study.) Less << | - | - | |
| NCT02849457 | Tuberous Sclerosis Complex | Phase 2 | Recruiting | May 2021 | United States, Alabama ... More >> University of Alabama at Birmingham Recruiting Birmingham, Alabama, United States, 35233 Contact: Jessica Krefting, RN 205-975-2890 jessicakrefting@uabmc.edu Contact: Regina Ryan, MS 205-975-2890 reginaryan@uabmc.edu Principal Investigator: E. Martina Bebin, MD, MPA United States, California University of California, Los Angeles Recruiting Los Angeles, California, United States, 90095 Contact: Natalie Solis 310-206-4037 nsolis@mednet.ucla.edu Principal Investigator: Joyce Wu, MD Children's Hospital of Orange County Recruiting Orange, California, United States, 92868 Contact: Shumyla Rashid 714-509-8642 srashid@choc.org Principal Investigator: Mary Zupanc, MD Stanford University Recruiting Palo Alto, California, United States, 94304 Contact: Swetapadma Patnaik 650-721-1458 sweta@stanford.edu Principal Investigator: Brenda Porter, MD United States, Massachusetts Boston Children's Hospital Recruiting Boston, Massachusetts, United States, 02215 Contact: Amelia Diplock 617-919-1476 amelia.diplock@childrens.harvard.edu Principal Investigator: Mustafa Sahin, MD, PhD United States, Michigan Beaumont Children's Hospital Recruiting Royal Oak, Michigan, United States, 48073 Contact: Emily Kreis, RN 248-551-2275 Emily.Kreis@beaumont.org Principal Investigator: Danielle Nolan, MD United States, Minnesota Minnesota Epilepsy Group, PA Recruiting Saint Paul, Minnesota, United States, 55102 Contact: Alisha Olson, RN 651-241-5206 aolson@mnepilepsy.net Principal Investigator: Michael Frost, MD United States, Missouri Washington University in St. Louis Recruiting Saint Louis, Missouri, United States, 63110 Contact: Olga Novak 314-454-4267 novako@wustl.edu Principal Investigator: Michael Wong, MD, PhD United States, Ohio Cincinnati's Children Hospital Medical Center Recruiting Cincinnati, Ohio, United States, 45229 Contact: Molly Griffith 513-636-9699 molly.griffith@cchmc.org Principal Investigator: Darcy Kreuger, MD, PhD United States, Pennsylvania The Children's Hospital of Philadelphia Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Casey Gorman 267-426-5171 GormanC@email.chop.edu Principal Investigator: Katherine Taub, MD United States, Texas University of Texas Health Science Center at Houston Recruiting Houston, Texas, United States, 77054 Contact: Elida Salazar 713-500-5766 Elida.L.Salazar@uth.tmc.edu Principal Investigator: Mary K Koenig, MD Less << |
| NCT01585207 | - | Completed | - | - | |
| NCT02220114 | Infantile Spasms | Not Applicable | Completed | - | France ... More >> Service de neurologie pédiatrique - CHU Amiens, France, 80054 Service de neurologie pédiatrique - CHU Angers, France, 49033² Service de neuropédiatrie - CHU Pellegrin Enfants Bordeaux, France, 33076 Service de neurologie infantile - Hôpital Salengro Lille, France, 59037 Service de nuerologie pédiatrique - Hôpital Femme Mère Enfant Lyon, France, 69677 Service de neurologie pédiatrique - Hôpital de la Timone Marseille, France, 13385 Service de neurologie pédiatrique - Hôpital Necker Enfants Malades Paris, France, 75015 Service de neuropédiatrie - Hôpital Robert Debré Paris, France, 75019 Service de neurologie pédiatrique - Hôpital Sud Rennes, France, 35203 Centre référent des épilepsies rares pédiatrique associé - Hôpital de Hautepierre Strasbourg, France, 67098 Service de neuropédiatrie - Hôpital Purpan Toulouse, France, 331059 Service de neuropédiatrie - Hôpital de Clocheville Tours, France, 37044 Less << |
| NCT01585207 | Tourette's Disorder | Phase 1 Phase 2 | Completed | - | United States, New York ... More >> Tics and Tourette's Clinical and Research Program New York, New York, United States, 10029 Less << |
| NCT01266291 | Complex Partial Seizures | Phase 4 | Terminated(Was not possible to... More >> enroll sufficient number of subjects to draw any worthwhile conclusions from the study.) Less << | - | United States, Pennsylvania ... More >> University of Pennsylvania Philadelphia, Pennsylvania, United States, 19103 Less << |
| NCT01413711 | Infantile Spasms | Phase 4 | Withdrawn | - | - |
| Bio Calculators | ||||
| Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
7.74mL 1.55mL 0.77mL |
38.71mL 7.74mL 3.87mL |
77.42mL 15.48mL 7.74mL |
|
| Dissolving Methods |
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
|
|||
Tags: Vigabatrin | γ-Vinyl-GABA | GABA Receptor | Neuronal Signaling | Tumor Development and Microenvironment Evolution | Membrane Transporter/Ion Channel | 68506-86-5
Precautionary Statements-General | |
| Code | Phrase |
| P101 | If medical advice is needed,have product container or label at hand. |
| P102 | Keep out of reach of children. |
| P103 | Read label before use |
Prevention | |
| Code | Phrase |
| P201 | Obtain special instructions before use. |
| P202 | Do not handle until all safety precautions have been read and understood. |
| P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
| P211 | Do not spray on an open flame or other ignition source. |
| P220 | Keep/Store away from clothing/combustible materials. |
| P221 | Take any precaution to avoid mixing with combustibles |
| P222 | Do not allow contact with air. |
| P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
| P230 | Keep wetted |
| P231 | Handle under inert gas. |
| P232 | Protect from moisture. |
| P233 | Keep container tightly closed. |
| P234 | Keep only in original container. |
| P235 | Keep cool |
| P240 | Ground/bond container and receiving equipment. |
| P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
| P242 | Use only non-sparking tools. |
| P243 | Take precautionary measures against static discharge. |
| P244 | Keep reduction valves free from grease and oil. |
| P250 | Do not subject to grinding/shock/friction. |
| P251 | Pressurized container: Do not pierce or burn, even after use. |
| P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
| P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
| P262 | Do not get in eyes, on skin, or on clothing. |
| P263 | Avoid contact during pregnancy/while nursing. |
| P264 | Wash hands thoroughly after handling. |
| P265 | Wash skin thouroughly after handling. |
| P270 | Do not eat, drink or smoke when using this product. |
| P271 | Use only outdoors or in a well-ventilated area. |
| P272 | Contaminated work clothing should not be allowed out of the workplace. |
| P273 | Avoid release to the environment. |
| P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
| P281 | Use personal protective equipment as required. |
| P282 | Wear cold insulating gloves/face shield/eye protection. |
| P283 | Wear fire/flame resistant/retardant clothing. |
| P284 | Wear respiratory protection. |
| P285 | In case of inadequate ventilation wear respiratory protection. |
| P231 + P232 | Handle under inert gas. Protect from moisture. |
| P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
| Code | Phrase |
| P301 | IF SWALLOWED: |
| P304 | IF INHALED: |
| P305 | IF IN EYES: |
| P306 | IF ON CLOTHING: |
| P307 | IF exposed: |
| P308 | IF exposed or concerned: |
| P309 | IF exposed or if you feel unwell: |
| P310 | Immediately call a POISON CENTER or doctor/physician. |
| P311 | Call a POISON CENTER or doctor/physician. |
| P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
| P313 | Get medical advice/attention. |
| P314 | Get medical advice/attention if you feel unwell. |
| P315 | Get immediate medical advice/attention. |
| P320 | |
| P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
| P321 | |
| P322 | |
| P330 | Rinse mouth. |
| P331 | Do NOT induce vomiting. |
| P332 | IF SKIN irritation occurs: |
| P333 | If skin irritation or rash occurs: |
| P334 | Immerse in cool water/wrap n wet bandages. |
| P335 | Brush off loose particles from skin. |
| P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
| P337 | If eye irritation persists: |
| P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
| P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P342 | If experiencing respiratory symptoms: |
| P350 | Gently wash with plenty of soap and water. |
| P351 | Rinse cautiously with water for several minutes. |
| P352 | Wash with plenty of soap and water. |
| P353 | Rinse skin with water/shower. |
| P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
| P361 | Remove/Take off immediately all contaminated clothing. |
| P362 | Take off contaminated clothing and wash before reuse. |
| P363 | Wash contaminated clothing before reuse. |
| P370 | In case of fire: |
| P371 | In case of major fire and large quantities: |
| P372 | Explosion risk in case of fire. |
| P373 | DO NOT fight fire when fire reaches explosives. |
| P374 | Fight fire with normal precautions from a reasonable distance. |
| P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
| P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
| P378 | |
| P380 | Evacuate area. |
| P381 | Eliminate all ignition sources if safe to do so. |
| P390 | Absorb spillage to prevent material damage. |
| P391 | Collect spillage. Hazardous to the aquatic environment |
| P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
| P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
| P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
| P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
| P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
| P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
| P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
| P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
| P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
| P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
| P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
| P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
| P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
| P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
| P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
| P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
| P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
| P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
| P370 + P376 | In case of fire: Stop leak if safe to Do so. |
| P370 + P378 | In case of fire: |
| P370 + P380 | In case of fire: Evacuate area. |
| P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
| P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
| Code | Phrase |
| P401 | |
| P402 | Store in a dry place. |
| P403 | Store in a well-ventilated place. |
| P404 | Store in a closed container. |
| P405 | Store locked up. |
| P406 | Store in corrosive resistant/ container with a resistant inner liner. |
| P407 | Maintain air gap between stacks/pallets. |
| P410 | Protect from sunlight. |
| P411 | |
| P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
| P413 | |
| P420 | Store away from other materials. |
| P422 | |
| P402 + P404 | Store in a dry place. Store in a closed container. |
| P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
| P403 + P235 | Store in a well-ventilated place. Keep cool. |
| P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
| P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
| P411 + P235 | Keep cool. |
Disposal | |
| Code | Phrase |
| P501 | Dispose of contents/container to ... |
| P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
| Code | Phrase |
| H200 | Unstable explosive |
| H201 | Explosive; mass explosion hazard |
| H202 | Explosive; severe projection hazard |
| H203 | Explosive; fire, blast or projection hazard |
| H204 | Fire or projection hazard |
| H205 | May mass explode in fire |
| H220 | Extremely flammable gas |
| H221 | Flammable gas |
| H222 | Extremely flammable aerosol |
| H223 | Flammable aerosol |
| H224 | Extremely flammable liquid and vapour |
| H225 | Highly flammable liquid and vapour |
| H226 | Flammable liquid and vapour |
| H227 | Combustible liquid |
| H228 | Flammable solid |
| H229 | Pressurized container: may burst if heated |
| H230 | May react explosively even in the absence of air |
| H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
| H240 | Heating may cause an explosion |
| H241 | Heating may cause a fire or explosion |
| H242 | Heating may cause a fire |
| H250 | Catches fire spontaneously if exposed to air |
| H251 | Self-heating; may catch fire |
| H252 | Self-heating in large quantities; may catch fire |
| H260 | In contact with water releases flammable gases which may ignite spontaneously |
| H261 | In contact with water releases flammable gas |
| H270 | May cause or intensify fire; oxidizer |
| H271 | May cause fire or explosion; strong oxidizer |
| H272 | May intensify fire; oxidizer |
| H280 | Contains gas under pressure; may explode if heated |
| H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
| H290 | May be corrosive to metals |
Health hazards | |
| Code | Phrase |
| H300 | Fatal if swallowed |
| H301 | Toxic if swallowed |
| H302 | Harmful if swallowed |
| H303 | May be harmful if swallowed |
| H304 | May be fatal if swallowed and enters airways |
| H305 | May be harmful if swallowed and enters airways |
| H310 | Fatal in contact with skin |
| H311 | Toxic in contact with skin |
| H312 | Harmful in contact with skin |
| H313 | May be harmful in contact with skin |
| H314 | Causes severe skin burns and eye damage |
| H315 | Causes skin irritation |
| H316 | Causes mild skin irritation |
| H317 | May cause an allergic skin reaction |
| H318 | Causes serious eye damage |
| H319 | Causes serious eye irritation |
| H320 | Causes eye irritation |
| H330 | Fatal if inhaled |
| H331 | Toxic if inhaled |
| H332 | Harmful if inhaled |
| H333 | May be harmful if inhaled |
| H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
| H335 | May cause respiratory irritation |
| H336 | May cause drowsiness or dizziness |
| H340 | May cause genetic defects |
| H341 | Suspected of causing genetic defects |
| H350 | May cause cancer |
| H351 | Suspected of causing cancer |
| H360 | May damage fertility or the unborn child |
| H361 | Suspected of damaging fertility or the unborn child |
| H361d | Suspected of damaging the unborn child |
| H362 | May cause harm to breast-fed children |
| H370 | Causes damage to organs |
| H371 | May cause damage to organs |
| H372 | Causes damage to organs through prolonged or repeated exposure |
| H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
| Code | Phrase |
| H400 | Very toxic to aquatic life |
| H401 | Toxic to aquatic life |
| H402 | Harmful to aquatic life |
| H410 | Very toxic to aquatic life with long-lasting effects |
| H411 | Toxic to aquatic life with long-lasting effects |
| H412 | Harmful to aquatic life with long-lasting effects |
| H413 | May cause long-lasting harmful effects to aquatic life |
| H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL


